FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893927117> ?p ?o ?g. }

• W2893927117 endingPage "391" @default.
• W2893927117 startingPage "380" @default.
• W2893927117 abstract "We previously reported initial results in 102 multiple myeloma (MM) patients treated with sequential high-dose melphalan and autologous hematopoietic cell transplantation followed by 200 cGy total body irradiation with or without fludarabine 90 mg/m2 and allogeneic hematopoietic cell transplantation. Here we present long-term clinical outcomes among the 102 initial patients and among 142 additional patients, with a median follow up of 8.3 (range 1.0-18.1) years. Donors included human leukocyte antigen identical siblings (n=179) and HLA-matched unrelated donors (n=65). A total of 209 patients (86%) received tandem autologous-allogeneic upfront, while thirty-five patients (14%) had failed a previous autologous hematopoietic cell transplantation before the planned autologous-allogeneic transplantation. Thirty-one patients received maintenance treatment at a median of 86 days (range, 61-150) after allogeneic transplantation. Five-year rates of overall survival (OS) and progression-free survival (PFS) were 54% and 31%, respectively. Ten-year OS and PFS were 41% and 19%, respectively. Overall non-relapse mortality was 2% at 100 days and 14% at five years. Patients with induction-refractory disease and those with high-risk biological features experienced shorter OS and PFS. A total of 152 patients experienced disease relapse and 117 of those received salvage treatment. Eighty-three of the 117 patients achieved a clinical response, and for those, the median duration of survival after relapse was 7.8 years. Moreover, a subset of patients who became negative for minimal residual disease (MRD) by flow cytometry experienced a significantly lower relapse rate as compared with MRD-positive patients (P=0.03). Our study showed that the graft-versus-myeloma effect after non-myeloablative allografting allowed long-term disease control in standard and high-risk patient subsets. Ultra-high-risk patients did not appear to benefit from tandem autologous/allogeneic hematopoietic cell transplantation because of early disease relapse. Incorporation of newer anti-MM agents into the initial induction treatments before tandem hematopoietic cell transplantation and during maintenance might improve outcomes of ultra-high-risk patients. Clinical trials included in this study are registered at: clinicaltrials.gov identifiers: 00075478, 00005799, 01251575, 00078858, 00105001, 00027820, 00089011, 00003196, 00006251, 00793572, 00054353, 00014235, 00003954." @default.
• W2893927117 created "2018-10-05" @default.
• W2893927117 creator A5006173110 @default.
• W2893927117 creator A5007024434 @default.
• W2893927117 creator A5010023051 @default.
• W2893927117 creator A5012590130 @default.
• W2893927117 creator A5016406533 @default.
• W2893927117 creator A5016684714 @default.
• W2893927117 creator A5025887498 @default.
• W2893927117 creator A5031690184 @default.
• W2893927117 creator A5038143009 @default.
• W2893927117 creator A5045089433 @default.
• W2893927117 creator A5051018931 @default.
• W2893927117 creator A5055821837 @default.
• W2893927117 creator A5062571587 @default.
• W2893927117 creator A5070467855 @default.
• W2893927117 creator A5081343057 @default.
• W2893927117 creator A5084915025 @default.
• W2893927117 creator A5085787488 @default.
• W2893927117 date "2018-09-27" @default.
• W2893927117 modified "2023-10-17" @default.
• W2893927117 title "Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma" @default.
• W2893927117 cites W107716097 @default.
• W2893927117 cites W1530764705 @default.
• W2893927117 cites W1647507681 @default.
• W2893927117 cites W1850498080 @default.
• W2893927117 cites W1855126786 @default.
• W2893927117 cites W1859633588 @default.
• W2893927117 cites W1968348918 @default.
• W2893927117 cites W1969349875 @default.
• W2893927117 cites W1982946267 @default.
• W2893927117 cites W2006393030 @default.
• W2893927117 cites W2010766702 @default.
• W2893927117 cites W2016896026 @default.
• W2893927117 cites W2024036444 @default.
• W2893927117 cites W2034022870 @default.
• W2893927117 cites W2034236066 @default.
• W2893927117 cites W2044585767 @default.
• W2893927117 cites W2046408556 @default.
• W2893927117 cites W2049498583 @default.
• W2893927117 cites W2053278212 @default.
• W2893927117 cites W2068014383 @default.
• W2893927117 cites W2069519666 @default.
• W2893927117 cites W2082738932 @default.
• W2893927117 cites W2086735887 @default.
• W2893927117 cites W2102591890 @default.
• W2893927117 cites W2104149194 @default.
• W2893927117 cites W2104452168 @default.
• W2893927117 cites W2107057207 @default.
• W2893927117 cites W2107854972 @default.
• W2893927117 cites W2114366538 @default.
• W2893927117 cites W2115385885 @default.
• W2893927117 cites W2117005724 @default.
• W2893927117 cites W2117648349 @default.
• W2893927117 cites W2120474651 @default.
• W2893927117 cites W2122021478 @default.
• W2893927117 cites W2125721471 @default.
• W2893927117 cites W2126351771 @default.
• W2893927117 cites W2128192762 @default.
• W2893927117 cites W2129865991 @default.
• W2893927117 cites W2134877860 @default.
• W2893927117 cites W2136256331 @default.
• W2893927117 cites W2137062141 @default.
• W2893927117 cites W2139026714 @default.
• W2893927117 cites W2141451077 @default.
• W2893927117 cites W2143425592 @default.
• W2893927117 cites W2145651125 @default.
• W2893927117 cites W2147082411 @default.
• W2893927117 cites W2155535356 @default.
• W2893927117 cites W2159773146 @default.
• W2893927117 cites W2169288585 @default.
• W2893927117 cites W2169846247 @default.
• W2893927117 cites W2228175078 @default.
• W2893927117 cites W2297531503 @default.
• W2893927117 cites W2318069817 @default.
• W2893927117 cites W2397983925 @default.
• W2893927117 cites W2486629951 @default.
• W2893927117 cites W2508231867 @default.
• W2893927117 cites W2604776612 @default.
• W2893927117 cites W2618857260 @default.
• W2893927117 cites W2755114342 @default.
• W2893927117 cites W2763322898 @default.
• W2893927117 cites W2765918174 @default.
• W2893927117 cites W2767838632 @default.
• W2893927117 cites W2772946231 @default.
• W2893927117 cites W3145716452 @default.
• W2893927117 doi "https://doi.org/10.3324/haematol.2018.200253" @default.
• W2893927117 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6355483" @default.
• W2893927117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262560" @default.
• W2893927117 hasPublicationYear "2018" @default.
• W2893927117 type Work @default.
• W2893927117 sameAs 2893927117 @default.
• W2893927117 citedByCount "23" @default.
• W2893927117 countsByYear W28939271172019 @default.
• W2893927117 countsByYear W28939271172020 @default.
• W2893927117 countsByYear W28939271172021 @default.
• W2893927117 countsByYear W28939271172022 @default.
• W2893927117 countsByYear W28939271172023 @default.

• next